Cargando…
Dynamic changes in pathology and PD‐L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report
During chemotherapy, certain cancer cells undergo cell death, which alters the properties of remaining cells and leads to numerous changes in the constituent cells of lung cancer. Immunotherapy has been used as neoadjuvant therapy, and several studies have reported changes in lung cancer tissue foll...
Autores principales: | Hong, Green, Park, Hee Sun, Yeo, Min Kyung, Lee, Dahye, Chung, Chaeuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423660/ https://www.ncbi.nlm.nih.gov/pubmed/37416998 http://dx.doi.org/10.1111/1759-7714.15023 |
Ejemplares similares
-
Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma
por: Kim, Kyung-Hee, et al.
Publicado: (2019) -
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
por: Fashoyin‐Aje, Lola, et al.
Publicado: (2018) -
Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports
por: Mota, Jose Mauricio, et al.
Publicado: (2018) -
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2021) -
The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)